{
    "nct_id": "NCT04802733",
    "official_title": "Phase 1 Study To Assess the Safety and Tolerability of Human Embryonic Stem Cell-Derived Midbrain Dopamine Neuron Cell Therapy (MSK-DA01) For Advanced Parkinson's Disease",
    "inclusion_criteria": "* Age 50-78 years old (Canada)\n* Age 60-78 years old (United States)\n* Diagnosis of Parkinson's Disease made between 3 to 20 years ago\n* Taking levodopa, but with complications of therapy such as wearing off and/or dyskinesia\n* Able to participate in all study visits and evaluations, including brain MRI and PET scan\n* Existence of a study partner who may act as potential surrogate over long term for ongoing consent\nHealthy volunteers allowed\nMust have minimum age of 50 Years\nMust have maximum age of 78 Years",
    "exclusion_criteria": "* Diagnosis of primary mitochondrial disorder, epilepsy, stroke, multiple sclerosis or other neurodegenerative diseases such as Alzheimer's disease\n* Prior Deep Brain Stimulation , lesion therapy, or gene therapy for PD\n* Prior surgical or radiation therapy to the brain or spinal cord\n* Any medical condition resulting in high risk of immunosuppressive drugs, including any active infectious disease\n* Inability to temporarily stop anti-platelet agents or other anti-coagulant medications without serious risk\n* Previous or currently active malignant disease within the past 5 years, except basal cell carcinoma or in situ uterine cervical carcinoma that have been treated\n* Severe obesity (>350 lbs) or any condition that prevents use of PET/MRI\n* Pregnancy or breastfeeding\n* Contraindication to surgery or general anesthesia\n* In the opinion of the investigator, any other condition regarded as making subject unsuitable for trial",
    "miscellaneous_criteria": ""
}